

LISTING OF THE CLAIMS READABLE ON ELECTED SPECIES

16. (currently amended) A process for analyzing gene function comprising: a) injecting a naked oligonucleotide that is not expressed into a blood vessel lumen, *in vivo* ; b) increasing the propensity for macromolecules to move through vessel walls and enter the extravascular space; and, c) delivering the naked oligonucleotide to an extravascular cell outside of the blood vessel via the increased permeability.
20. (currently amended) The process of claim [[4]] 16 wherein the oligonucleotide consists of double strand nucleic acid.
21. (currently amended) The process of claim [[8]] 20 wherein the double strand oligonucleotide comprises RNA.
22. (currently amended) The process of claim [[4]] 16 wherein delivery of the oligonucleotide to the cell results in decreased expression of the gene.
23. (currently amended) The process of claim [[9]] 21 wherein the double strand oligonucleotide consists of a nucleic acid sequence comprising 10 to 50 bases.
24. (currently amended) The process of claim [[11]] 23 wherein the double strand oligonucleotide consists of a nucleic acid sequence comprising 18 to 25 bases.
25. (currently amended) The process of claim [[4]] 16 wherein the oligonucleotide comprises sequence that is similar to a portion of the gene sequence.
26. (currently amended) The process of claim [[10]] 22 wherein the gene is an endogenous gene.
27. (currently amended) The process of claim [[15]] 22 wherein the gene is a viral gene.

COMPLETE LISTING OF THE CLAIMS

- 1-12. (canceled)
13. (withdrawn) A process for analyzing gene function comprising: a) injecting a naked polynucleotide encoding the gene into a blood vessel lumen, *in vivo* ; b) increasing the propensity for macromolecules to move through vessel walls and enter the extravascular space; and, c) delivering the naked polynucleotide to an extravascular cell outside of the blood vessel.
14. (withdrawn) The process of claim [[1]] 13 wherein the polynucleotide consists of a gene.
15. (withdrawn) The process of claim [[1]] 13 wherein the gene encodes a protein.
16. (currently amended) A process for analyzing gene function comprising: a) injecting a naked oligonucleotide that is not expressed into a blood vessel lumen, *in vivo* ; b) increasing the propensity for macromolecules to move through vessel walls and enter the extravascular space; and, c) delivering the naked oligonucleotide to an extravascular cell outside of the blood vessel via the increased permeability.
17. (withdrawn) The process of claim [[4]] 16 wherein the oligonucleotide consists of a single strand oligonucleotide.
18. (withdrawn) The process of claim [[5]] 17 wherein the single strand oligonucleotide consists of anti-sense oligonucleotide.
19. (withdrawn) The process of claim [[6]] 18 wherein the ~~single strand~~ anti-sense oligonucleotide consists of an artificial oligonucleotide.
20. (currently amended) The process of claim [[4]] 16 wherein the oligonucleotide consists of double strand nucleic acid.
21. (currently amended) The process of claim [[8]] 20 wherein the double strand oligonucleotide comprises RNA.
22. (currently amended) The process of claim [[4]] 16 wherein delivery of the oligonucleotide to the cell results in decreased expression of the gene.
23. (currently amended) The process of claim [[9]] 21 wherein the double strand oligonucleotide consists of a nucleic acid sequence comprising 10 to 50 bases.
24. (currently amended) The process of claim [[11]] 23 wherein the double strand oligonucleotide consists of a nucleic acid sequence comprising 18 to 25 bases.

25. (currently amended) The process of claim [[4]] 16 wherein the oligonucleotide comprises sequence that is similar to a portion of the gene sequence.
26. (currently amended) The process of claim [[10]] 22 wherein the gene is an endogenous gene.
27. (currently amended) The process of claim [[15]] 22 wherein the gene is a viral gene.
28. (withdrawn) The process of claim [[1]] 13 wherein analyzing gene function comprises drug design.
29. (withdrawn) The process of claim [[4]] 16 wherein analyzing gene function comprises drug design.

If there are any questions or concerns, please contact the undersigned.

Respectfully submitted,



Kirk Ekena, Reg. No. 56,672  
Mirus Bio Corporation  
505 South Rosa Road  
Madison, WI 53719  
608-238-4400

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as express mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date: May 9, 2006

  
Kirk Ekena